| Drug ID: | Drug83 |
|---|---|
| Drug Name: | Nolpitantium besylate |
| CID: | 3047794 |
| DrugBank ID: | NULL |
| Modality: | Small Molecule |
| Groups: | NULL |
| US Approved: | NULL |
| Other Approved: | NULL |
| Identifier: | NCT00232258 |
| Molecular Formula: | C43H50Cl2N2O5S |
| Molecular Weight: | 777.8 g/mol |
| Isomeric SMILES: | CC(C)OC1=CC=CC(=C1)CC(=O)N2CCC[C@](C2)(CC[N+]34CCC(CC3)(CC4)C5=CC=CC=C5)C6=CC(=C(C=C6)Cl)Cl.C1=CC=C(C=C1)S(=O)(=O)[O-] |
| Synonyms: | Nolpitantium besilate; Nolpitantium besylate; 155418-06-7; Nolpitantium besilate [INN]; UNII-SN2G80PK4I; Nolpitantium benzenesulfonate; SN2G80PK4I; besilato de nolpitantio; besilate de nolpitantium; SR 140333B |
| Phase 0: | 0 |
| Phase 1: | 0 |
| Phase 2: | 0 |
| Phase 3: | 0 |
| Phase 4: | 0 |
| Description: | NULL |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt700 | 3047794 | Nolpitantium Besilate | 6869 | TACR1 | Homo sapiens (human) | Antagonist | |
| dt701 | 3047794 | Nolpitantium Besilate | 5594 | MAPK1 | Rattus norvegicus (Norway rat) | 16788306 | SR140333B inhibits the reaction [capsaicin results in increased phosphorylation of MAPK1 protein] |
| dt702 | 3047794 | Nolpitantium Besilate | 5595 | MAPK3 | Rattus norvegicus (Norway rat) | 16788306 | SR140333B inhibits the reaction [capsaicin results in increased phosphorylation of MAPK3 protein] |
| dt703 | 3047794 | Nolpitantium Besilate | 4353 | MPO | Rattus norvegicus (Norway rat) | 15046732 | SR140333B inhibits the reaction [ethanol results in increased activity of MPO protein]|sr140333b inhibits the reaction [iodoacetamide results in increased activity of MPO protein] |
| dt704 | 3047794 | Nolpitantium Besilate | 6774 | STAT3 | Rattus norvegicus (Norway rat) | 16788306 | SR140333B inhibits the reaction [capsaicin results in increased phosphorylation of STAT3 protein] |
| dt705 | 3047794 | Nolpitantium Besilate | 6869 | TACR1 | Rattus norvegicus (Norway rat) | 16788306 | SR140333B binds to and results in decreased activity of TACR1 protein |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT00232258 | Nolpitantium Besylate In Patients With Ulcerative Colitis a Double-Blind, Placebo Controlled Efficacy and Safety Study | PHASE2 | COMPLETED | Sanofi | Ulcerative Colitis|Inflammatory Bowel Disease | DRUG: Nolpitantium besylate | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
No related literature
You can run management commands to establish drug-literature associations